Estrella Immunopharma Expands STARLIGHT-1 Trial with New Texas Clinical Site
The trial is evaluating EB103, which is a CD19-redirected ARTEMIS® T-cell therapy, in adult patients (aged 18 and older) with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL).
